About Us

About

Our Mission

Our mission is to make the lives of patients fighting serious, life-threatening diseases better by the discovery, development and delivery of innovative therapies. Our lead therapy, Zorblisa™ (SD-101), is a proprietary topical therapy being developed for the treatment of patients with EB.

What is EB?

Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder that typically manifests at birth or early childhood and for which there are currently no approved treatments.

Learn More go

Patient & Family Resources

Find out more about current research trials, patient advocacy resources and more.

Learn More go